GlobeNewswire

Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026
11/05/2026
Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
CPTx appoints Edward Rebar as Chief Scientific Officer
11/05/2026
Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform David Maier appointed to expanded role as CPTx Chief Business Officer [...]
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
11/05/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
11/05/2026
CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential accelerated drug development WALTHAM, [...]
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
11/05/2026
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ” ), a clinical-stage biotech [...]
Kraig Biocraft Laboratories Commissions New Production Rearing Center to Support Accelerating Spider Silk Scale-Up
11/05/2026
ANN ARBOR, Mich., May 11, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful [...]
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
11/05/2026
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for comparison to [...]
4basebio Launches Enzymatic ssDNA Platform
11/05/2026
4basebio PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and [...]
Rezolute to Participate in Upcoming Investor Conferences
11/05/2026
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China
11/05/2026
WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development ( [...]
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
11/05/2026
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision [...]
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
11/05/2026
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of [...]
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
11/05/2026
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and [...]
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
11/05/2026
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
11/05/2026
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One [...]
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
11/05/2026
PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( TSXV: [...]
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
11/05/2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes First-in- [...]
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
11/05/2026
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum